Strategy for the treatment of Helicobacter pylori infection

Current Pharmaceutical Design

Volumn 20, Issue 28, 2014, Pages 4489-4500

  Shiota, Seiji ^a   Yamaoka, Yoshio ^a,b  

^a OITA UNIVERSITY   (Japan)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Guideline; Helicobacter pylori; Management; Resistance; Treatment

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; CYTOCHROME P450 2C19; LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL VIRULENCE; CHRONIC GASTRITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; ERADICATION THERAPY; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MEDICATION COMPLIANCE; META ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; STOMACH CANCER; COMPLICATION; DRUG COMBINATION; GASTRITIS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTIC ULCER; PRACTICE GUIDELINE; STOMACH NEOPLASMS;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; GASTRITIS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; PRACTICE GUIDELINES AS TOPIC; PROTON PUMP INHIBITORS; STOMACH NEOPLASMS;

EID: 84904745427     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113196660731     Document Type: Article

References (155)

1. Suerbaum S, Michetti P. Helicobacter pyloriinfection. N Engl J Med 2002; 347: 1175-86.
2. Kusters JG, van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pyloriinfection. Clin Microbiol Rev 2006; 19: 449-90.
3. Goh KL, Chan WK, Shiota S, Yamaoka Y. Epidemiology of Helicobacter pyloriinfection and public health implications. Helicobacter 2011; 16 Suppl 1: 1-9.
4. Graham D, Adam E, Reddy G, et al. Seroepidemiology of Helicobacter pyloriinfection in India. Comparison of developing and developed countries. Dig Dis Sci 1991; 36: 1084-8.
5. Graham D, Malaty H, Evans D, Evans DJ, Klein P, Adam E. Epidemiology of Helicobacter pyloriin an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100: 1495-501.
6. Hosking SW, Chung SCS, Yung MY, et al. Duodenal ulcer healing by eradication of Helicobacter pyloriwithout anti-acid treatment: randomised controlled trial. The Lancet 1994; 343: 508-10.
7. Shiota S, Yamaoka Y. Management of Helicobacter pylori. F1000 Med Rep 2010; 2.
8. Shiota S, Murakami K, Fujioka T, Yamaoka Y. Population-based strategies for Helicobacter pylori-associated disease management: a Japanese perspective. Expert Rev Gastroenterol Hepatol 2010; 4: 149-56.
9. Takenaka R, Okada H, Kato J, et al. Helicobacter pylorieradication reduced the incidence of gastric cancer, especially of the intestinal type. Alimentary Pharmacology & Therapeutics 2007; 25: 805-12.
10. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection--the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-64.
11. Sugiyama T, Sakaki N, Kozawa H, et al. Sensitivity of biopsy site in evaluating regression of gastric atrophy after Helicobacter pylori eradication treatment. Aliment Pharmacol Ther 2002; 16 Suppl 2: 187-90.
12. Vannella L, Lahner E, Bordi C, et al. Reversal of atrophic body gastritis after H. pylorieradication at long-term follow-up. Digestive and Liver Disease 2011; 43: 295-9.
13. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-604.
14. Chey W, Wong B. American College of Gastroenterology guideline on the management of Helicobacter pyloriinfection. Am J Gastroenterol 2007; 102: 1808-25.
15. Fock K, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pyloriinfection. J Gastroenterol Hepatol 2009; 24: 1587-600.
16. Asaka M, Kato M, Takahashi S, et al. Guidelines for the Management of Helicobacter pyloriInfection in Japan: 2009 Revised Edition. Helicobacter 2010; 15: 1-20.
17. Kodama M, Murakami K, Okimoto T, et al. Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylorieradication. J Gastroenterol 2012; 47: 394-403.
18. Kodama M, Murakami K, Okimoto T, et al. Helicobacter pylori eradication improves gastric atrophy and intestinal metaplasia in long-term observation. Digestion 2012; 85: 126-30.
19. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pyloriinfection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
20. Asaka M. A new approach for elimination of gastric cancer deaths in Japan. Int J Cancer 2013; 132: 1272-6.
21. Gisbert J, Khorrami S, Carballo F, Calvet X, Gené E, DominguezMuñoz J. H. pylorieradication therapy vs. antisecretory noneradication therapy (with or without long-term maintenance antisecretory therapy) for the prevention of recurrent bleeding from peptic ulcer. Cochrane Database Syst Rev 2004: CD004062.
22. Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylorieradication: a multicenter study of 4940 patients. Helicobacter 2004; 9: 9-16.
23. Wu C, Kuo K, Wu M, Chen Y, Wang C, Lin J. Early Helicobacter pylorieradication decreases risk of gastric cancer in patients with peptic ulcer disease. Gastroenterology 2009; 137: 1641-8. e1-2.
24. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylorion incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392-7.
25. Ito M, Takata S, Tatsugami M, et al. Clinical prevention of gastric cancer by Helicobacter pylori eradication therapy: a systematic review. J Gastroenterol 2009; 44: 365-71.
26. Asaka M, Kato M, Graham DY. Strategy for eliminating gastric cancer in Japan. Helicobacter 2010; 15: 486-90.
27. Take S, Mizuno M, Ishiki K, et al. The long-term risk of gastric cancer after the successful eradication of Helicobacter pylori. J Gastroenterol 2011; 46: 318-24.
28. Fuccio L, Zagari R, Eusebi L, et al. Meta-analysis: can Helicobacter pylorieradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-8.
29. Stolte M, Eidt S. Healing gastric MALT lymphomas by eradicating H pylori? Lancet 1993; 342: 568.
30. Wotherspoon A, Doglioni C, Diss T, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-7.
31. Bayerdörffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pyloriinfection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-4.
32. Inagaki H, Nakamura T, Li C, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylorieradication and detection of API2-MALT1 fusion. Am J Surg Pathol 2004; 28: 1560-7.
33. Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-13.
34. Gasbarrini A, Franceschi F, Tartaglione R, Landolfi R, Pola P, Gasbarrini G. Regression of autoimmune thrombocytopenia after eradication of Helicobacter pylori. Lancet 1998; 352: 878.
35. Ando K, Shimamoto T, Tauchi T, et al. Can eradication therapy for Helicobacter pylorireally improve the thrombocytopenia in idiopathic thrombocytopenic purpura? Our experience and a literature review. Int J Hematol 2003; 77: 239-44.
36. Fujimura K, Kuwana M, Kurata Y, et al. Is eradication therapy useful as the first line of treatment in Helicobacter pylori-positive idiopathic thrombocytopenic purpura? Analysis of 207 eradicated chronic ITP cases in Japan. Int J Hematol 2005; 81: 162-8.
37. Sato R, Murakami K, Watanabe K, et al. Effect of Helicobacter pylorieradication on platelet recovery in patients with chronic idiopathic thrombocytopenic purpura. Arch Intern Med 2004; 164: 1904-7.
38. Everhart J, Kruszon-Moran D, Perez-Perez G, Tralka T, McQuillan G. Seroprevalence and ethnic differences in Helicobacter pyloriinfection among adults in the United States. J Infect Dis 2000; 181: 1359-63.
39. Michel M, Khellaf M, Desforges L, et al. Autoimmune thrombocytopenic Purpura and Helicobacter pyloriinfection. Arch Intern Med 2002; 162: 1033-6.
40. Takahashi T, Yujiri T, Tanizawa Y. Helicobacter pyloriand chronic ITP: the discrepancy in the clinical responses to eradication therapy might be due to differences in the bacterial strains. Blood 2004; 104: 594.
41. Byrne M, Kerrigan S, Corcoran P, et al. Helicobacter pyloribinds von Willebrand factor and interacts with GPIb to induce platelet aggregation. Gastroenterology 2003; 124: 1846-54.
42. Veneri D, De Matteis G, Solero P, et al. Analysis of B-and T-cell clonality and HLA class II alleles in patients with idiopathic thrombocytopenic purpura: correlation with Helicobacter pyloriinfection and response to eradication treatment. Platelets 2005; 16: 307-11.
43. Franchini M, Cruciani M, Mengoli C, Pizzolo G, Veneri D. Effect of Helicobacter pylorieradication on platelet count in idiopathic thrombocytopenic purpura: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60: 237-46.
44. Stasi R, Sarpatwari A, Segal J, et al. Effects of eradication of Helicobacter pyloriinfection in patients with immune thrombocytopenic purpura: a systematic review. Blood 2009; 113: 1231-40.
45. Cremonini F, Di Caro S, Delgado-Aros S, et al. Meta-analysis: the relationship between Helicobacter pyloriinfection and gastrooesophageal reflux disease. Aliment Pharmacol Ther 2003; 18: 279-89.
46. Kawanishi M. Development of reflux esophagitis following Helicobacter pylorieradication. J Gastroenterol 2005; 40: 1024-8.
47. Sasaki A, Haruma K, Manabe N, Tanaka S, Yoshihara M, Chayama K. Long-term observation of reflux oesophagitis developing after Helicobacter pylorieradication therapy. Aliment Pharmacol Ther 2003; 17: 1529-34.
48. Tsukada K, Miyazaki T, Katoh H, et al. The incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori. Eur J Gastroenterol Hepatol 2005; 17: 1025-8.
49. Rimbara E, Fischbach LA, Graham DY. Optimal therapy for Helicobacter pyloriinfections. Nat Rev Gastroenterol Hepatol 2011; 8: 79-88.
50. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pyloritherapy. Helicobacter 2007; 12: 275-8.
51. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylorieradication. Ann Intern Med 2007; 147: 553-62.
52. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylorieradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007; 12: 31-5.
53. Murakami K, Sato R, Okimoto T, et al. Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for secondline Helicobacter pylorieradication in Japan, and the influence of metronidazole resistance. Aliment Pharmacol Ther 2003; 17: 119-23.
54. Shimoyama T, Fukuda S, Mikami T, Fukushi M, Munakata A. Efficacy of metronidazole for the treatment of clarithromycinresistant Helicobacter pyloriinfection in a Japanese population. J Gastroenterol 2004; 39: 927-30.
55. Fukuda S, Shimoyama T, Tanaka M, Nakasato F, Fukushi M, Munakata A. Duration of the metronidazole-containing regimen for eradication of Helicobacter pyloriinfection in northern Japan. Jpn J Infect Dis 2006; 59: 367-9.
56. Murakami K, Okimoto T, Kodama M, Sato R, Watanabe K, Fujioka T. Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pyloriinfection. J Clin Gastroenterol 2008; 42: 139-42.
57. Sugizaki K, Sakata Y, Arai T, Furuhata Y, Iinuma N, Suzuki H. A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan. Intern Med 2012; 51: 3103-8.
58. Nakajima S, Inoue H, Inoue T, Maruoka Y. Multiple-antibioticresistant Helicobacter pyloriinfection eradicated with a tailormade quadruple therapy. J Gastroenterol Hepatol 2012; 27 Suppl 3: 108-11.
59. Sugimoto M, Furuta T. Efficacy of esomeprazole in treating acidrelated diseases in Japanese populations. Clin Exp Gastroenterol 2012; 5: 49-59.
60. Hiraishi H, Haruma K, Miwa H, Goto H. Clinical trial: irsogladine maleate, a mucosal protective drug, accelerates gastric ulcer healing after treatment for eradication of Helicobacter pyloriinfection--the results of a multicentre, double-blind, randomized clinical trial (IMPACT study). Aliment Pharmacol Ther 2010; 31: 824-33.
61. Murakami K, Okimoto T, Kodama M, et al. Comparison of the efficacy of irsogladine maleate and famotidine for the healing of gastric ulcers after Helicobacter pylorieradication therapy: a randomized, controlled, prospective study. Scand J Gastroenterol 2011; 46: 287-92.
62. Akagi M, Amagase K, Murakami T, Takeuchi K. Irsogladine: overview of the mechanisms of mucosal protective and healing-promoting actions in the gastrointestinal tract. Curr Pharm Des 2013; 19: 106-14.
63. Jafri NS, Hornung CA, Howden CW. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pyloriinfection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31.
64. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D. Sequential therapy or triple therapy for Helicobacter pyloriinfection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79; quiz 1080.
65. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacincontaining versus clarithromycin-containing sequential therapy for Helicobacter pylorieradication: a randomised trial. Gut 2010; 59: 1465-70.
66. Liou JM, Chen CC, Chen MJ, et al. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-13.
67. Luther J, Higgins PD, Schoenfeld PS, Moayyedi P, Vakil N, Chey WD. Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pyloriinfection: Systematic review and meta-analysis of efficacy and tolerability. Am J Gastroenterol 2010; 105: 65-73.
68. Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, noninferiority, phase 3 trial. Lancet 2011; 377: 905-13.
69. Gisbert JP, Calvet X. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
70. Federico A, Nardone G, Gravina AG, et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pyloriinfection. Gastroenterology 2012; 143: 55-61. e1; quize e13-4.
71. Jenks PJ. Causes of failure of eradication of Helicobacter pylori. BMJ 2002; 325: 3-4.
72. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pyloriinfection and factors influencing eradication. Aliment Pharmacol Ther 2002; 16 Suppl 1: 24-30.
73. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylorieradication. Am J Med 2006; 119: 217-24.
74. Megraud F. H. pyloriantibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384.
75. Debets-Ossenkopp YJ, Herscheid AJ, Pot RG, Kuipers EJ, Kusters JG, Vandenbroucke-Grauls CM. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 1999; 43: 511-5.
76. van der Wouden EJ, van Zwet AA, Vosmaer GD, Oom JA, de Jong A, Kleibeuker JH. Rapid increase in the prevalence of metronidazole-resistant Helicobacter pyloriin the Netherlands. Emerg Infect Dis 1997; 3: 385-9.
77. Asaka M, Sugiyama T, Kato M, et al. Amulticenter, double-blind study on triple therapy with lansoprazole, amoxicillin and clarithromycin for eradication of Helicobacter pyloriin Japanese peptic ulcer patients. Helicobacter 2001; 6: 254-61.
78. Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-Year First-Line Eradication Rate of Helicobacter pyloriBased on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin. J Clin Biochem Nutr 2010; 47: 53-8.
79. Fujioka T, Aoyama N, Sakai K, et al. A large-scale nationwide multicenter prospective observational study of triple therapy using rabeprazole, amoxicillin, and clarithromycin for Helicobacter pylorieradication in Japan. J Gastroenterol 2012; 47: 276-83.
80. Megraud F, Lehours P. Helicobacter pyloridetection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322.
81. Versalovic J, Shortridge D, Kibler K, et al. Mutations in 23S rRNA are associated with clarithromycin resistance in Helicobacter pylori. Antimicrob Agents Chemother 1996; 40: 477-80.
82. Stone GG, Shortridge D, Flamm RK, et al. Identification of a 23S rRNA gene mutation in clarithromycin-resistant Helicobacter pylori. Helicobacter 1996; 1: 227-8.
83. De Francesco V, Zullo A, Ierardi E, et al. Phenotypic and genotypic Helicobacter pyloriclarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65: 327-32.
84. Umegaki N, Shimoyama T, Nishiya D, Suto T, Fukuda S, Munakata A. Clarithromycin-resistance and point mutations in the 23S rRNA gene in Helicobacter pyloriisolates from Japan. J Gastroenterol Hepatol 2000; 15: 906-9.
85. Ribeiro ML, Vitiello L, Miranda MC, et al. Mutations in the 23S rRNA gene are associated with clarithromycin resistance in Helicobacter pyloriisolates in Brazil. Ann Clin Microbiol Antimicrob 2003; 2: 11.
86. Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. Rapid detection of clarithromycin resistant Helicobacter pyloristrains in Spanish patients by polymerase chain reaction-restriction fragment length polymorphism. Rev Esp Quimioter 2011; 24: 32-6.
87. De Francesco V, Giorgio F, Ierardi E, et al. Primary clarithromycin resistance in Helicobacter pylori: the Multicentric Italian Clarithromycin Resistance Observational (MICRO) study. J Gastrointestin Liver Dis 2011; 20: 235-9.
88. Fontana C, Favaro M, Minelli S, et al. New site of modification of 23S rRNA associated with clarithromycin resistance of Helicobacter pyloriclinical isolates. Antimicrob Agents Chemother 2002; 46: 3765-9.
89. Hultén K, Gibreel A, Sköld O, Engstrand L. Macrolide resistance in Helicobacter pylori: mechanism and stability in strains from clarithromycin-treated patients. Antimicrob Agents Chemother 1997; 41: 2550-3.
90. Kim JM, Kim JS, Kim N, et al. Gene mutations of 23S rRNA associated with clarithromycin resistance in Helicobacter pyloristrains isolated from Korean patients. J Microbiol Biotechnol 2008; 18: 1584-9.
91. Francesco VD, Zullo A, Hassan C, Giorgio F, Rosania R, Ierardi E. Mechanisms of Helicobacter pyloriantibiotic resistance: An updated appraisal. World J Gastrointest Pathophysiol 2011; 2: 35-41.
92. García-Arata MI, Baquero F, de Rafael L, et al. Mutations in 23S rRNA in Helicobacter pyloriconferring resistance to erythromycin do not always confer resistance to clarithromycin. Antimicrob Agents Chemother 1999; 43: 374-6.
93. Kim KS, Kang JO, Eun CS, Han DS, Choi TY. Mutations in the 23S rRNA gene of Helicobacter pyloriassociated with clarithromycin resistance. J Korean Med Sci 2002; 17: 599-603.
94. Rimbara E, Noguchi N, Kijima H, Yamaguchi T, Kawai T, Sasatsu M. Mutations in the 23S rRNA gene of clarithromycin-resistant Helicobacter pylorifrom Japan. Int J Antimicrob Agents 2007; 30: 250-4.
95. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-57.
96. McMahon BJ, Hennessy TW, Bensler JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pyloriinfections. Ann Intern Med 2003; 139: 463-9.
97. Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
98. Kobayashi I, Murakami K, Kato M, et al. Changing antimicrobial susceptibility epidemiology of Helicobacter pyloristrains in Japan between 2002 and 2005. J Clin Microbiol 2007; 45: 4006-10.
99. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylorito quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011; 26: 1457-61.
100. Binh TT, Shiota S, Nguyen LT, et al. The incidence of primary antibiotic resistance of Helicobacter pyloriin Vietnam. J Clin Gastroenterol 2013; 47: 233-8.
101. Katelaris PH. Helicobacter pylori: antibiotic resistance and treatment options. J Gastroenterol Hepatol 2009; 24: 1155-7.
102. Megraud F. Epidemiology and mechanism of antibiotic resistance in Helicobacter pylori. Gastroenterology 1998; 115: 1278-82.
103. Megraud F. Resistance of Helicobacter pylorito antibiotics. Aliment Pharmacol Ther 1997; 11 Suppl 1: 43-53.
104. Nishizawa T, Suzuki H, Suzuki M, Takahashi M, Hibi T. Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. J Clin Biochem Nutr 2012; 51: 114-6.
105. Gisbert JP, De La Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Alimentary Pharmacology & Therapeutics 2006; 23: 35-44.
106. Gisbert JP. Second-line rescue therapy of helicobacter pyloriinfection. Therap Adv Gastroenterol 2009; 2: 331-56.
107. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin-versus metronidazole-based rescue therapy for H. pyloriinfection in Japan. Dig Liver Dis 2005; 37: 821-5.
108. Fujimura S, Kato S, Iinuma K, Watanabe A. In vitroactivity of fluoroquinolone and the gyrAgene mutation in Helicobacter pylori strains isolated from children. J Med Microbiol 2004; 53: 1019-22.
109. Bogaerts P, Berhin C, Nizet H, Glupczynski Y. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pyloristrains from patients living in Belgium. Helicobacter 2006; 11: 441-5.
110. Kim JM, Kim JS, Kim N, Kim SG, Jung HC, Song IS. Comparison of primary and secondary antimicrobial minimum inhibitory concentrations for Helicobacter pyloriisolated from Korean patients. Int J Antimicrob Agents 2006; 28: 6-13.
111. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pyloriisolates in Germany. Antimicrob Agents Chemother 2007; 51: 346-9.
112. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylorire-treatment: role of bacterial resistance. Dig Liver Dis 2007; 39: 1001-5.
113. Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacinbased rescue therapy for Helicobacter pyloriafter failures of first-and second-line therapies. Antimicrob Agents Chemother 2012; 56: 1643-5.
114. Murakami K, Okimoto T, Kodama M, et al. Sitafloxacin activity against Helicobacter pyloriisolates, including those with gyrAmutations. Antimicrob Agents Chemother 2009; 53: 3097-9.
115. Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylorieradication in Japan. J Gastroenterol 2013; 48: 1128-35.
116. Ahmad N, Zakaria WR, Mohamed R. Analysis of antibiotic susceptibility patterns of Helicobacter pyloriisolates from Malaysia. Helicobacter 2011; 16: 47-51.
117. Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pyloristrains in a random adult Swedish population. Helicobacter 2006; 11: 224-30.
118. Boyanova L, Ilieva J, Gergova G, et al. Numerous risk factors for Helicobacter pyloriantibiotic resistance revealed by extended anamnesis. A Bulgarian study. J Med Microbiol 2012; 61(Pt 1):85-93.
119. Seck A, Mbengue M, Gassama-Sow A, Diouf L, Ka MM, Boye CS. Antibiotic susceptibility of Helicobacter pyloriisolates in Dakar, Senegal. J Infect Dev Ctries 2009; 3: 137-40.
120. Kato S, Fujimura S. Primary antimicrobial resistance of Helicobacter pyloriin children during the past 9 years. Pediatr Int 2010; 52: 187-90.
121. Gerrits MM, Godoy APO, Kuipers EJ, et al. Multiple Mutations in or Adjacent to the Conserved Penicillin-Binding Protein Motifs of the Penicillin-Binding Protein 1A Confer Amoxicillin Resistance to Helicobacter pylori. Helicobacter 2006; 11: 181-187.
122. Okamoto T, Yoshiyama H, Nakazawa T, et al. A change in PBP1 is involved in amoxicillin resistance of clinical isolates of Helicobacter pylori. Journal of Antimicrobial Chemotherapy 2002; 50: 849-856.
123. Dore MP, Osato MS, Realdi G, Mura I, Graham DY, Sepulveda AR. Amoxycillin tolerance in Helicobacter pylori. J Antimicrob Chemother 1999; 43: 47-54.
124. Yakoob J, Fan X, Hu G, Liu L, Zhang Z. Antibiotic susceptibility of Helicobacter pyloriin the Chinese population. J Gastroenterol Hepatol 2001; 16: 981-985.
125. Thyagarajan SP, Ray P, Das BK, et al. Geographical difference in antimicrobial resistance pattern of Helicobacter pyloriclinical isolates from Indian patients: Multicentric study. J Gastroenterol Hepatol 2003; 18: 1373-8.
126. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 930-5.
127. Elviss N, Owen R, Xerry J, Walker A, Davies K. Helicobacter pyloriantibiotic resistance patterns and genotypes in adult dyspeptic patients from a regional population in North Wales. J Antimicrob Chemother 2004; 54: 435-40.
128. Agudo S, Pérez-Pérez G, Alarcón T, López-Brea M. High prevalence of clarithromycin-resistant Helicobacter pyloristrains and risk factors associated with resistance in Madrid, Spain. J Clin Microbiol 2010; 48: 3703-7.
129. De Francesco V, Margiotta M, Zullo A, et al. Claritromycin resistance and Helicobacter pylorigenotypes in Italy. J Microbiol 2006; 44: 660-4.
130. Suzuki T, Matsuo K, Sawaki A, et al. Systematic review and metaanalysis: importance of CagA status for successful eradication of Helicobacter pyloriinfection. Aliment Pharmacol Ther 2006; 24: 273-80.
131. De Francesco V, Zullo A, Margiotta M, et al. Sequential treatment for Helicobacter pyloridoes not share the risk factors of triple therapy failure. Aliment Pharmacol Ther 2004; 19: 407-14.
132. van der Hulst R, van der Ende A, Dekker F, et al. Effect of Helicobacter pylorieradication on gastritis in relation to cagA: a prospective 1-year follow-up study. Gastroenterology 1997; 113: 25-30.
133. Zhao J, Wang J, Yang L, Li Y. Influence of Helicobacter pylori genotype on triple eradication therapy. J Gastroenterol Hepatol 2007; 22: 2251-55.
134. Maeda S, Yoshida H, Ikenoue T, et al. Structure of cagpathogenicity island in Japanese Helicobacter pyloriisolates. Gut 1999; 44: 336-41.
135. Shiota S, Nguyen LT, Murakami K, et al. Association of Helicobacter pylori dupAWith the Failure of Primary Eradication. J Clin Gastroenterol 2012; 46: 297-301.
136. Grayson M, Eliopoulos G, Ferraro M, Moellering RJ. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Infect Dis 1989; 8: 888-9.
137. Hunt R. pH and Hp--gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol 1993; 88: 481-3.
138. Peterson W. The role of antisecretory drugs in the treatment of Helicobacter pyloriinfection. Aliment Pharmacol Ther 1997; 11 Suppl 1: 21-5.
139. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pyloriinfection. Aliment Pharmacol Ther 2012; 36: 414-25.
140. Schubert M, Peura D. Control of gastric acid secretion in health and disease. Gastroenterology 2008; 134: 1842-60.
141. Lu H, Hsu P, Graham D, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005; 128: 833-48.
142. Imagawa S, Ito M, Yoshihara M, Eguchi H, Tanaka S, Chayama K. Helicobacter pylori dupAand gastric acid secretion are negatively associated with gastric cancer development. J Med Microbiol 2010; 59: 1484-9.
143. Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate Helicobacter pyloriinfection: impact of pharmacogenomicsbased acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007; 8: 2701-17.
144. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006; 101: 1467-75.
145. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7: 59-64.
146. Dickson EJ, Stuart RC. Genetics of response to proton pump inhibitor therapy: clinical implications. Am J Pharmacogenomics 2003; 3: 303-15.
147. Andersson T, Hassan-Alin M, Hasselgren G, Röhss K. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet 2001; 40: 523-37.
148. Huang J, Zheng G, Sumanac K, Irvine E, Hunt R. Meta-analysis of the relationship between cagAseropositivity and gastric cancer. Gastroenterology 2003; 125: 1636-44.
149. Fock K, Talley N, Moayyedi P, et al. Asia-Pacific consensus guidelines on gastric cancer prevention. J Gastroenterol Hepatol 2008; 23: 351-65
150. El-Omar E, Carrington M, Chow W, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000; 404: 398-402.
151. Hwang I, Kodama T, Kikuchi S, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pyloriinfection. Gastroenterology 2002; 123: 1793-803.
152. Wong B, Lam S, Wong W, et al. Helicobacter pylorieradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-94.
153. Karita M, Teramukai S, Matsumoto S. Risk of Helicobacter pylori transmission from drinking well water is higher than that from infected intrafamilial members in Japan. Dig Dis Sci 2003; 48: 1062-7.
154. Niv Y, Hazazi R. Helicobacter pylorirecurrence in developed and developing countries: meta-analysis of 13C-urea breath test followup after eradication. Helicobacter 2008; 13: 56-61.
155. Blaser M, Falkow S. What are the consequences of the disappearing human microbiota? Nat Rev Microbiol 2009; 7: 887-94